In this review, we summarize the VLP cancer vaccines successfully licensed or under development for the prevention of cancer caused by viral infections, as well as the VLP vaccines under preclinical or early clinical evaluation as therapeutic strategy for various cancer types, with a focus on HER-2-positive breast cancer models. The gene discussed is ERBB2; the disease is breast carcinoma.